Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
11 employees
Onchilles Pharma: Pioneering cancer treatment through innovative neutrophil pathway research.
HQ
Founded
2017
Onchilles Pharma, founded on groundbreaking research into a novel neutrophil pathway, is dedicated to revolutionizing cancer treatment. The company's core mission is to develop first-in-class pan-cancer therapeutics that leverage innate immuno-biology. Their innovative approach aims to create medicines that can selectively and comprehensively kill cancer cells, regardless of genetic background, anatomical origin, or immunotype. Onchilles Pharma focuses on global drug discovery and development to bring these next-generation therapies to market.
Notable affiliated individuals and investors include leading scientists and biotech investors committed to advancing cancer treatment. The company has achieved significant milestones in preclinical studies, demonstrating the potential of their novel mechanism of action. Onchilles Pharma's impact lies in its promise to offer a universal cancer treatment solution, potentially transforming the oncology landscape and providing new hope for patients worldwide.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Cancer Treatment
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Onchilles Pharma founded?
Onchilles Pharma was founded in 2017.
Where is Onchilles Pharma's headquarters located?
Onchilles Pharma's headquarters is located in San Diego, CA, US.
When was Onchilles Pharma's last funding round?
Onchilles Pharma's most recent funding round was for $7M (USD) in July 2020.
How many employees does Onchilles Pharma have?
Onchilles Pharma has 11 employees as of Feb 5, 2024.
How much has Onchilles Pharma raised to-date?
As of July 05, 2023, Onchilles Pharma has raised a total of $7.2M (USD) since Jul 10, 2020.
Add Comparison
Total Raised to Date
$7.2M
USD
Last Update Jul 10, 2020
Last Deal Details
$7M
USD
Jul 10, 2020
Series A
Current Employees
11
Last updated: Feb 5, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts